Impact of Exogenous Ketones on Breathing in Healthy Volunteers

NCT ID: NCT07220122

Last Updated: 2026-01-14

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: EARLY_PHASE1
• Total Enrollment: 20 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2026-02-15
• Study Completion Date: 2027-02-10

Brief Summary

Exogenous ketones (EK) are compounds that can increase the level of ketones in the body without needing to change what an individual eats.

Although EK have been researched mainly in relation to energy and exercise, there haven't been many studies focusing specifically on how EKs affect breathing using well-established scientific methods. The investigators believe that EK may help improve breathing, which could be beneficial for situations like high altitudes, sleep apnea, and exercise.

To explore how EK might influence breathing, the investigators are conducting a randomized, placebo-controlled crossover study with healthy volunteers.

Detailed Description

Healthy volunteers will undergo daytime hypercapnic ventilatory response (HCVR) testing before and after ingesting 40g of exogenous ketones or placebo. Circulating ketone levels (beta-hydroxybutyrate) will be measured at baseline, 1 hour, and 2.5 hours after ingestion (immediately before HCVR testing). Studies will require two visits with a minimum of 48 hr. (and up to a max of 14 days) of washout.

The specific ketone product to be tested is 1,3 butanediol (1,3BD) in a commercially available formulation called "Ketone IQ". A taste-matched placebo will also be supplied by the sponsor. 1,3BD is converted by liver metabolism into the ketone body beta-hydroxybutyrate (BHB) and has been utilized in multiple studies.

PROCEDURES:

This is a randomized, single-blind, crossover study. Each participant will complete two testing sessions with a minimum of 48-hour washout period between visits. The single-blind design enables research staff to measure BHB levels and assess pharmacokinetic timing for potential adjustments to procedure timing, while keeping participants blinded to the intervention.

Baseline visit: A medical history and physical examination will be performed. A urine pregnancy screening test will be conducted for women under 60 years of age. A "run-in" procedure will be performed to confirm that participants can tolerate the taste of the ketone supplement. Participants will then be randomized to one of two arms:

• Group A: Visit 1 Ketones, Visit 2 Placebo
• Group B: Visit 1 Placebo, Visit 2 Ketones

Session 1:

HCVR Procedure: Participants will wear a facemask connected to a breathing circuit with a three-way stopcock, allowing inhaled gas to be switched from ambient air to a pre-mixed gas source. A one-way valve will divert exhaled gas to prevent rebreathing. The participant will breathe room air for 3-5 minutes to collect baseline ventilation data. The investigators will then switch to a non-diffusing gas bag containing 7% Carbon Dioxide (CO₂) / 93% O₂ and the participant will breathing this hypercapnic gas until end-tidal CO₂ (ETCO₂) reaches a stable plateau and is maintained (up to 3 minutes, as tolerated).

Exhaled CO₂ and airflow will be continuously monitored using a pneumotachograph to derive tidal volume and respiratory rate. The HCVR slope will be calculated as minute ventilation (L/min) plotted against end-tidal CO₂ (mmHg).

Session Sequence:

1. Participants will arrive at the lab after an overnight fast.

2. Baseline HCVR testing will be conducted before study product ingestion.

3. Participants will ingest 40 g Ketone-IQ or placebo.

4. Repeat HCVR testing 2.5 hours post-ingestion.

Capillary BHB levels will be measured at baseline, 1 hour, and 2.5 hours post-ingestion of Ketone-IQ. Participants will not see the BHB levels (so that the placebo condition will be appropriately masked).

Session 2:

This session will mirror Session 1, with participants crossing over to the alternate condition (i.e., Ketone-IQ or placebo), following a minimum 48-hour washout period.

Conditions

Healthy Volunteer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: SINGLE

Study Groups

Ketones first

Visit 1: ketones, Visit 2: Placebo

Group Type: EXPERIMENTAL

1,3 butanediol

Intervention Type: DIETARY_SUPPLEMENT

40 mg Ketone-IQ beverage

Placebo

Intervention Type: DIETARY_SUPPLEMENT

Placebo (taste matched)

Placebo first

Visit 1: Placebo, Visit 2: ketones

Group Type: EXPERIMENTAL

1,3 butanediol

Intervention Type: DIETARY_SUPPLEMENT

40 mg Ketone-IQ beverage

Placebo

Intervention Type: DIETARY_SUPPLEMENT

Placebo (taste matched)

Interventions

1,3 butanediol

40 mg Ketone-IQ beverage

Intervention Type: DIETARY_SUPPLEMENT

Placebo

Placebo (taste matched)

Intervention Type: DIETARY_SUPPLEMENT

Eligibility Criteria

Inclusion Criteria

• BMI of 18 - 30 kg/m2

Exclusion Criteria

• No concomitant sleep disorder (e.g. sleep apnea, insomnia, restless leg syndrome, narcolepsy, idiopathic hypersomnia). If there is no known diagnosis of sleep apnea, a STOP-BANG score of 5 or higher is an exclusion.
• No current daytime respiratory impairment such as uncontrolled asthma, or uncontrolled Chronic Obstructive Pulmonary Disease (COPD), pneumonia, interstitial lung disease.
• No known history of chronic renal disease or diabetes (type 1 or type 2).
• No use of supplemental oxygen.
• Cannot be on a low carbohydrate (<130 g carbohydrate/day) or ketogenic diet, intermittent fasting, or consuming exogenous ketones
• Cannot be pregnancy or breastfeeding
• Cannot be on medications: acetazolamide or Sodium-glucose cotransporter-2 (SGLT2) inhibitor, daily opioid use.
• No history of claustrophobia or panic disorder
• No frequent alcohol intake (more than 1 drink per day on average, or > 10 drinks per week).

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 50 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Johns Hopkins University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Jonathan C Jun, MD

Role: PRINCIPAL_INVESTIGATOR

Johns Hopkins University

Locations

Johns Hopkins Bayview Medical Center

Baltimore, Maryland, United States

Countries

United States

Central Contacts

Mariah Potocki

Role: CONTACT

mchaney7@jhmi.edu

410-550-2233

Other Identifiers

IRB00517978-2

Identifier Type: -

Identifier Source: org_study_id